Subgroup analyses. IRC-assessed BOR (A-C), IRC-assessed PFS (D), OS (E). *Refractory to last prior treatment. BOR, best objective response; CR, complete response; NE, not evaluable; OS, overall survival; PFS, progression-free survival; PR, partial response; 2L, patients had received one prior line of therapy before treatment with Pola + BR; 3L+ patients had received two or more prior lines of therapy before treatment with Pola + BR.